Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Working Capital Changes (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other Working Capital Changes for 16 consecutive years, with -$236000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes rose 40.7% to -$236000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$906000.0, a 237.07% decrease, with the full-year FY2023 number at -$473000.0, up 70.6% from a year prior.
  • Other Working Capital Changes was -$236000.0 for Q3 2025 at Gyre Therapeutics, up from -$5.8 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $5.5 million in Q1 2025 to a low of -$5.8 million in Q2 2025.
  • A 5-year average of -$52925.2 and a median of $7649.0 in 2021 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 13939.15% in 2021, then tumbled 2802.15% in 2024.
  • Gyre Therapeutics' Other Working Capital Changes stood at -$623000.0 in 2021, then tumbled by 121.35% to -$1.4 million in 2022, then grew by 18.64% to -$1.1 million in 2023, then surged by 64.53% to -$398000.0 in 2024, then skyrocketed by 40.7% to -$236000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Other Working Capital Changes are -$236000.0 (Q3 2025), -$5.8 million (Q2 2025), and $5.5 million (Q1 2025).